Abstract

Metagenomic Next-Generation Sequencing (mNGS) has emerged as a transformative diagnostic tool for infectious diseases, offering the ability to detect a broad spectrum of pathogens with high sensitivity and specificity. By enabling culture-independent detection, mNGS provides a promising alternative to traditional diagnostic methods. However, its widespread adoption faces several challenges, including high costs, data interpretation complexities, and the need for standardized clinical guidelines. This review evaluates the potential of mNGS in diagnosing infectious diseases, discusses its advantages over conventional methods, and highlights the clinical, technical, and regulatory challenges that need to be addressed for its broader implementation.